Sunshine Lake Pharma Co., Ltd.
80
10
11
59
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
6.3%
5 terminated/withdrawn out of 80 trials
92.2%
+5.7% vs industry average
6%
5 trials in Phase 3/4
0%
0 of 59 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (80)
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate Liver Damage
Role: lead
The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder
Role: lead
The Study of a Selective 5-ht6 Receptor Antagonist, HEC30654AcOH,in Healthy Subjects
Role: lead
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets in Chinses Healthy Subjects
Role: lead
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
Role: lead
A Clinical Trial of HEC93077 in Chinese Healthy Subjects and HUA Patients With Single or Multiple Dosing
Role: lead
the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets
Role: lead
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal Impairment
Role: lead
Single-ascending Dose Study of HEC-151 Injection
Role: lead
HEC169096 in Participants With Advanced Solid Tumors
Role: lead
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Role: lead
A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants
Role: lead
A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects
Role: lead
A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
Role: lead
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
Role: lead
Phase ll Study of HEC585 in Patients With IPF
Role: lead
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
Role: lead
Clinical Study on the Mass Balance of Clifutinib
Role: lead
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
Role: lead
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
Role: lead